Time to Sell Karyopharm Therapeutics Inc (KPTI) After The Completion of This Multiple Bottom?

September 17, 2017 - By Vivian Currie

Investors sentiment increased to 2.4 in 2016 Q4. Its up 0.88, from 1.52 in 2016Q3. It improved, as 5 investors sold Karyopharm Therapeutics Inc shares while 15 reduced holdings. 14 funds opened positions while 34 raised stakes. 24.99 million shares or 9.31% more from 22.86 million shares in 2016Q3 were reported.
Cam Gp Holdings A S holds 0% of its portfolio in Karyopharm Therapeutics Inc (NASDAQ:KPTI) for 13,000 shares. D E Shaw Co reported 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Secor Capital Advsr Lp owns 66,484 shares or 0.08% of their US portfolio. Susquehanna International Group Llp stated it has 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Manufacturers Life Insurance Com The stated it has 0% of its portfolio in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Bnp Paribas Arbitrage Sa invested in 1,345 shares. 102,556 are held by Morgan Stanley. 55,793 are held by Essex Inv Mngmt Commerce Lc. Parametric Port Ltd Liability accumulated 20,199 shares. New York State Common Retirement Fund reported 29,430 shares. Citigroup holds 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI) or 631 shares. United Services Automobile Association reported 0% of its portfolio in Karyopharm Therapeutics Inc (NASDAQ:KPTI). State Street accumulated 406,103 shares. Moreover, Tcw Grp has 0% invested in Karyopharm Therapeutics Inc (NASDAQ:KPTI) for 40,648 shares. Schwab Charles Investment Mngmt Inc invested in 82,752 shares or 0% of the stock.

The stock of Karyopharm Therapeutics Inc (KPTI) shows a multiple bottoms pattern with $10.01 target or 9.00 % below today’s $11.00 share price. The 5 months chart pattern indicates high risk for the $518.53 million company. It was reported on Sep, 17 by Finviz.com. If the $10.01 price target is reached, the company will be worth $46.67M less.
Multiple bottoms are very good trading chart patterns. These patterns have a low break even failure rate and decent average rise in a bull market, giving them a solid performance rank. Back-tests of such patterns show that the break even failure rate is 4%, the average rise: 37%, the throwback rate: 64% and the percentage of stocks meeting their price targets: 64%.

The stock increased 4.07% or $0.43 on September 15, reaching $11. About 432,710 shares traded or 146.40% up from the average. Karyopharm Therapeutics Inc (NASDAQ:KPTI) has risen 21.19% since September 17, 2016 and is uptrending. It has outperformed by 4.49% the S&P500.

Analysts await Karyopharm Therapeutics Inc (NASDAQ:KPTI) to report earnings on November, 6. They expect $-0.64 EPS, up 7.25 % or $0.05 from last year’s $-0.69 per share. After $-0.64 actual EPS reported by Karyopharm Therapeutics Inc for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Karyopharm Therapeutics Inc (NASDAQ:KPTI) Ratings Coverage

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. had 22 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was initiated by Raymond James with “Outperform” on Friday, May 27. The company was downgraded on Wednesday, January 6 by Jefferies. The stock of Karyopharm Therapeutics Inc (NASDAQ:KPTI) earned “Buy” rating by Jefferies on Wednesday, September 9. The firm has “Outperform” rating by Robert W. Baird given on Tuesday, June 28. The firm earned “Outperform” rating on Tuesday, August 11 by Leerink Swann. The stock has “Buy” rating by Jefferies on Tuesday, August 30. The stock of Karyopharm Therapeutics Inc (NASDAQ:KPTI) has “Overweight” rating given on Wednesday, September 2 by JP Morgan. The firm has “Buy” rating given on Tuesday, August 8 by Canaccord Genuity. Jefferies maintained Karyopharm Therapeutics Inc (NASDAQ:KPTI) on Tuesday, March 15 with “Hold” rating. JP Morgan maintained it with “Overweight” rating and $19 target in Monday, March 14 report.

More notable recent Karyopharm Therapeutics Inc (NASDAQ:KPTI) news were published by: Fool.com which released: “Why Karyopharm Therapeutics Inc Stock Gained 16.4% in March” on April 07, 2017, also Seekingalpha.com with their article: “Karyopharm Therapeutics: Buy, Sell, Or Hold?” published on June 30, 2017, Seekingalpha.com published: “Karyopharm Therapeutics’ (KPTI) CEO Michael Kauffman on Q2 2017 Results …” on August 08, 2017. More interesting news about Karyopharm Therapeutics Inc (NASDAQ:KPTI) were released by: Seekingalpha.com and their article: “Karyopharm’s Selinexor Should Drive Substantial Growth” published on March 27, 2017 as well as Streetinsider.com‘s news article titled: “Karyopharm Therapeutics (KPTI) Names Michael Falvey as Chief Financial Officer” with publication date: September 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.